First Long-term Oncologic Results of the ALPPS Procedure in a Large Cohort of Patients With Colorectal Liver Metastases.
Journal
Annals of surgery
ISSN: 1528-1140
Titre abrégé: Ann Surg
Pays: United States
ID NLM: 0372354
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
pubmed:
25
8
2020
medline:
11
11
2020
entrez:
25
8
2020
Statut:
ppublish
Résumé
To analyze long-term oncological outcome along with prognostic risk factors in a large cohort of patients with colorectal liver metastases (CRLM) undergoing ALPPS. ALPPS is a two-stage hepatectomy variant that increases resection rates and R0 resection rates in patients with primarily unresectable CRLM as evidenced in a recent randomized controlled trial. Long-term oncologic results, however, are lacking. Cases in- and outside the International ALPPS Registry were collected and completed by direct contacts to ALPPS centers to secure a comprehensive cohort. Overall, cancer-specific (CSS), and recurrence-free (RFS) survivals were analyzed along with independent risk factors using Cox-regression analysis. The cohort included 510 patients from 22 ALPPS centers over a 10-year period. Ninety-day mortality was 4.9% and median overall survival, CSS, and RFS were 39, 42, and 15 months, respectively. The median follow-up time was 38 months (95% confidence interval 32-43 months). Multivariate analysis identified tumor-characteristics (primary T4, right colon), biological features (K/N-RAS status), and response to chemotherapy (Response Evaluation Criteria in Solid Tumors) as independent predictors of CSS. Traditional factors such as size of metastases, uni versus bilobar involvement, and liver-first approach were not predictive. When hepatic recurrences after ALPPS was amenable to surgical/ablative treatment, median CSS was significantly superior compared to chemotherapy alone (56 vs 30 months, P < 0.001). This large cohort provides the first evidence that patients with primarily unresectable CRLM treated by ALPPS have not only low perioperative mortality, but achieve appealing long-term oncologic outcome especially those with favorable tumor biology and good response to chemotherapy.
Sections du résumé
OBJECTIVES
To analyze long-term oncological outcome along with prognostic risk factors in a large cohort of patients with colorectal liver metastases (CRLM) undergoing ALPPS.
BACKGROUND
ALPPS is a two-stage hepatectomy variant that increases resection rates and R0 resection rates in patients with primarily unresectable CRLM as evidenced in a recent randomized controlled trial. Long-term oncologic results, however, are lacking.
METHODS
Cases in- and outside the International ALPPS Registry were collected and completed by direct contacts to ALPPS centers to secure a comprehensive cohort. Overall, cancer-specific (CSS), and recurrence-free (RFS) survivals were analyzed along with independent risk factors using Cox-regression analysis.
RESULTS
The cohort included 510 patients from 22 ALPPS centers over a 10-year period. Ninety-day mortality was 4.9% and median overall survival, CSS, and RFS were 39, 42, and 15 months, respectively. The median follow-up time was 38 months (95% confidence interval 32-43 months). Multivariate analysis identified tumor-characteristics (primary T4, right colon), biological features (K/N-RAS status), and response to chemotherapy (Response Evaluation Criteria in Solid Tumors) as independent predictors of CSS. Traditional factors such as size of metastases, uni versus bilobar involvement, and liver-first approach were not predictive. When hepatic recurrences after ALPPS was amenable to surgical/ablative treatment, median CSS was significantly superior compared to chemotherapy alone (56 vs 30 months, P < 0.001).
CONCLUSIONS
This large cohort provides the first evidence that patients with primarily unresectable CRLM treated by ALPPS have not only low perioperative mortality, but achieve appealing long-term oncologic outcome especially those with favorable tumor biology and good response to chemotherapy.
Identifiants
pubmed: 32833765
doi: 10.1097/SLA.0000000000004330
pii: 00000658-202011000-00019
doi:
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
793-800Références
Hess KR, Varadhachary GR, Taylor SH, et al. Metastatic patterns in adenocarcinoma. Cancer 2006; 106:1624–1633.
Clavien PA, Petrowsky H, DeOliveira ML, et al. Strategies for safer liver surgery and partial liver transplantation. N Engl J Med 2007; 356:1545–1559.
Mizuno T, Cloyd JM, Omichi K, et al. Two-stage hepatectomy vs one-stage major hepatectomy with contralateral resection or ablation for advanced bilobar colorectal liver metastases. J Am Coll Surg 2018; 226:825–834.
Linecker M, Kuemmerli C, Clavien PA, et al. Dealing with insufficient liver remnant: associating liver partition and portal vein ligation for staged hepatectomy. J Surg Oncol 2019; 119:604–612.
Schnitzbauer AA, Lang SA, Goessmann H, et al. Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann Surg 2012; 255:405–414.
Schadde E, Ardiles V, Robles-Campos R, et al. Early survival and safety of ALPPS: first report of the International ALPPS registry. Ann Surg 2014; 260:829–836. discussion 836-838.
Linecker M, Bjornsson B, Stavrou GA, et al. Risk adjustment in ALPPS is associated with a dramatic decrease in early mortality and morbidity. Ann Surg 2017; 266:779–786.
Sandstrom P, Rosok BI, Sparrelid E, et al. ALPPS improves resectability compared with conventional two-stage hepatectomy in patients with advanced colorectal liver metastasis: results from a scandinavian multicenter randomized controlled trial (LIGRO Trial). Ann Surg 2018; 267:833–840.
Hasselgren K, Rosok BI, Larsen PN, et al. ALPPS improves survival compared with TSH in patients affected of CRLM: survival analysis from the randomized controlled trial LIGRO. Ann Surg 2019; 10.1097/SLA0000000000003701), online ahead of print.
doi: 10.1097/SLA0000000000003701)
Truant S, Scatton O, Dokmak S, et al. Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS): impact of the inter-stages course on morbi-mortality and implications for management. Eur J Surg Oncol 2015; 41:674–682.
Gasser E, Braunwarth E, Riedmann M, et al. Primary tumour location affects survival after resection of colorectal liver metastases: a two-institutional cohort study with international validation, systematic meta-analysis and a clinical risk score. PLoS One 2019; 14:e0217411.
Yang JF, Noffsinger AE, Agrawal D, et al. Colorectal cancer anatomic distribution patterns remain the same after sessile serrated adenoma/polyp considered cancer precursor: a 9-year comparison study from community-based endoscopy centers. J Gastrointest Oncol 2016; 7:917–923.
Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205–216.
Rubbia-Brandt L, Giostra E, Brezault C, et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol 2007; 18:299–304.
Raptis DA, Linecker M, Kambakamba P, et al. Defining benchmark outcomes for ALPPS. Ann Surg 2019; 270:835–841.
Krell RW, D’Angelica MI. Treatment sequencing for simultaneous colorectal liver metastases. J Surg Oncol 2019; 119:583–593.
Brouquet A, Abdalla EK, Kopetz S, et al. High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol 2011; 29:1083–1090.
Turrini O, Ewald J, Viret F, et al. Two-stage hepatectomy: who will not jump over the second hurdle? Eur J Surg Oncol 2012; 38:266–273.
Quenet F, Pissas MH, Gil H, et al. Two-stage hepatectomy for colorectal liver metastases: Pathologic response to preoperative chemotherapy is associated with second-stage completion and longer survival. Surgery 2019; 165:703–711.
Zimmitti G, Panettieri E, Ardito F, et al. Type of response to conversion chemotherapy strongly impacts survival after hepatectomy for initially unresectable colorectal liver metastases. ANZ J Surg 2020; 20:558–563.
Berardi G, De Man M, Laurent S, et al. Radiologic and pathologic response to neoadjuvant chemotherapy predicts survival in patients undergoing the liver-first approach for synchronous colorectal liver metastases. Eur J Surg Oncol 2018; 44:1069–1077.
Amikura K, Akagi K, Ogura T, et al. The RAS mutation status predicts survival in patients undergoing hepatic resection for colorectal liver metastases: The results from a genetic analysis of all-RAS. J Surg Oncol 2018; 117:745–755.
Goffredo P, Utria AF, Beck AC, et al. The prognostic impact of KRAS mutation in patients having curative resection of synchronous colorectal liver metastases. J Gastrointest Surg 2019; 23:1957–1963.
Lang H, Baumgart J, Heinrich S, et al. Extended molecular profiling improves stratification and prediction of survival after resection of colorectal liver metastases. Ann Surg 2019; 270:799–805.
Passot G, Chun YS, Kopetz SE, et al. Predictors of safety and efficacy of 2-stage hepatectomy for bilateral colorectal liver metastases. J Am Coll Surg 2016; 223:99–108.
Serenari M, Alvarez FA, Ardiles V, et al. The ALPPS approach for colorectal liver metastases: impact of KRAS mutation status in survival. Dig Surg 2018; 35:303–310.
Petrowsky H, Fritsch R, Guckenberger M, et al. Modern therapeutic approaches for treatment of malignant liver tumours. Nat Rev Gastroenetol Hepatol 2020; doi: 10.1038/s41575-020-0314-8, online ahead of print.
doi: 10.1038/s41575-020-0314-8
Baran B, Mert Ozupek N, Yerli Tetik N, et al. Difference between left-sided and right-sided colorectal cancer: a focused review of Literature. Gastroenterology Res 2018; 11:264–273.
Elizabeth McCracken EK, Samsa GP, Fisher DA, et al. Prognostic significance of primary tumor sidedness in patients undergoing liver resection for metastatic colorectal cancer. HPB (Oxford) 2019; 21:1667–1675.
Dupre A, Malik HZ, Jones RP, et al. Influence of the primary tumour location in patients undergoing surgery for colorectal liver metastases. Eur J Surg Oncol 2018; 44:80–86.
Esposito F, Lim C, Sa Cunha A, et al. Primary tumor versus liver-first approach for synchronous colorectal liver metastases: an association francaise de chirurgie (AFC) multicenter-based study with propensity score analysis. World J Surg 2018; 42:4046–4053.
Ghiasloo M, Kahya H, Van Langenhove S, et al. Effect of treatment sequence on survival in stage IV rectal cancer with synchronous and potentially resectable liver metastases. J Surg Oncol 2019; 120:415–422.
Kambakamba P, Linecker M, Alvarez FA, et al. Short chemotherapy-free interval improves oncological outcome in patients undergoing two-stage hepatectomy for colorectal liver metastases. Ann Surg Oncol 2016; 23:3915–3923.
de Haas RJ, Wicherts DA, Flores E, et al. R1 resection by necessity for colorectal liver metastases: is it still a contraindication to surgery? Ann Surg 2008; 248:626–637.
Truant S, Sequier C, Leteurtre E, et al. Tumour biology of colorectal liver metastasis is a more important factor in survival than surgical margin clearance in the era of modern chemotherapy regimens. HPB (Oxford) 2015; 17:176–184.
D’Angelica MI. Positive margins after resection of metastatic colorectal cancer in the liver: back to the drawing board? Ann Surg Oncol 2017; 24:2432–2433.
Wanis KN, Ardiles V, Alvarez FA, et al. Intermediate-term survival and quality of life outcomes in patients with advanced colorectal liver metastases undergoing associating liver partition and portal vein ligation for staged hepatectomy. Surgery 2018; 163:691–697.
Petrowsky H, Gonen M, Jarnagin W, et al. Second liver resections are safe and effective treatment for recurrent hepatic metastases from colorectal cancer: a bi-institutional analysis. Ann Surg 2002; 235:863–871.
Battula N, Tsapralis D, Mayer D, et al. Repeat liver resection for recurrent colorectal metastases: a single-centre, 13-year experience. HPB (Oxford) 2014; 16:157–163.
Wicherts DA, de Haas RJ, Salloum C, et al. Repeat hepatectomy for recurrent colorectal metastases. Br J Surg 2013; 100:808–818.
Lillemoe HA, Kawaguchi Y, Passot G, et al. Surgical resection for recurrence after two-stage hepatectomy for colorectal liver metastases is feasible, is safe, and improves survival. J Gastrointest Surg 2019; 23:84–92.